MX2016005396A - Compositions for oral administration of zoledronic acid or related compounds for treating disease. - Google Patents
Compositions for oral administration of zoledronic acid or related compounds for treating disease.Info
- Publication number
- MX2016005396A MX2016005396A MX2016005396A MX2016005396A MX2016005396A MX 2016005396 A MX2016005396 A MX 2016005396A MX 2016005396 A MX2016005396 A MX 2016005396A MX 2016005396 A MX2016005396 A MX 2016005396A MX 2016005396 A MX2016005396 A MX 2016005396A
- Authority
- MX
- Mexico
- Prior art keywords
- zoledronic acid
- compositions
- oral administration
- related compounds
- treating disease
- Prior art date
Links
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004276 zoledronic acid Drugs 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- -1 bisphosphonate compounds Chemical class 0.000 abstract 2
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical group [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/063,979 US8802658B2 (en) | 2012-05-14 | 2013-10-25 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US14/279,241 US20140249317A1 (en) | 2012-05-14 | 2014-05-15 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| PCT/US2014/050427 WO2015060924A1 (en) | 2013-10-25 | 2014-08-08 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016005396A true MX2016005396A (en) | 2017-03-01 |
Family
ID=52993341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005396A MX2016005396A (en) | 2013-10-25 | 2014-08-08 | Compositions for oral administration of zoledronic acid or related compounds for treating disease. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3060220A4 (en) |
| JP (6) | JP6166471B2 (en) |
| KR (3) | KR20190009428A (en) |
| CN (2) | CN105960240B (en) |
| AU (2) | AU2014340649C1 (en) |
| CA (1) | CA2928350C (en) |
| HK (1) | HK1257400A1 (en) |
| IL (2) | IL245287A0 (en) |
| MX (1) | MX2016005396A (en) |
| MY (1) | MY176246A (en) |
| SG (3) | SG10201609548UA (en) |
| WO (1) | WO2015060924A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
| US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| KR20190009428A (en) * | 2013-10-25 | 2019-01-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| KR20190045355A (en) | 2016-10-28 | 2019-05-02 | 미쯔비시 케미컬 주식회사 | A sizing agent for carbon fibers, an aqueous dispersion of sizing agent for carbon fibers, and a carbon fiber with sizing agent |
| GB202100352D0 (en) * | 2021-01-12 | 2021-02-24 | Balticgruppen Bio Ab | New methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1057488A4 (en) * | 1998-12-25 | 2003-10-22 | Toray Industries | Interleukin-6 production inhibitors |
| GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| CA2435552C (en) * | 2001-02-06 | 2010-04-27 | The Royal Alexandra Hospital For Children | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| PL363507A1 (en) * | 2001-05-02 | 2004-11-29 | Novartis Ag | Pharmaceutical uses of bisphosphonates |
| US7875597B2 (en) * | 2002-07-24 | 2011-01-25 | New York University | Treatment of spinal mechanical pain |
| TW200410701A (en) * | 2002-10-15 | 2004-07-01 | Novartis Ag | Method of administering bisphosphonates |
| EP1567533B1 (en) * | 2003-07-03 | 2009-03-11 | Teva Pharmaceutical Industries Ltd. | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| AR046773A1 (en) * | 2003-12-23 | 2005-12-21 | Novartis Ag | PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATES |
| CA2769633C (en) * | 2009-07-31 | 2017-06-06 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| DK2531200T3 (en) * | 2010-02-06 | 2017-09-11 | Gruenenthal Gmbh | COSTALLIZATION PROCEDURE AND BIOTA ACCESSIBILITY |
| WO2012071517A2 (en) * | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| US20130303486A1 (en) * | 2012-05-14 | 2013-11-14 | Herriot Tabuteau | Compositions Comprising Zoledronic Acid or Related Compounds for Relieving Pain Associated with Arthritis |
| KR20190009428A (en) * | 2013-10-25 | 2019-01-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
-
2014
- 2014-08-08 KR KR1020197001788A patent/KR20190009428A/en not_active Withdrawn
- 2014-08-08 AU AU2014340649A patent/AU2014340649C1/en active Active
- 2014-08-08 KR KR1020167012645A patent/KR101739244B1/en active Active
- 2014-08-08 CN CN201480069491.3A patent/CN105960240B/en active Active
- 2014-08-08 EP EP14856165.7A patent/EP3060220A4/en not_active Withdrawn
- 2014-08-08 CN CN201810150156.6A patent/CN108434154A/en active Pending
- 2014-08-08 CA CA2928350A patent/CA2928350C/en active Active
- 2014-08-08 KR KR1020177013050A patent/KR101975687B1/en active Active
- 2014-08-08 SG SG10201609548UA patent/SG10201609548UA/en unknown
- 2014-08-08 MX MX2016005396A patent/MX2016005396A/en unknown
- 2014-08-08 WO PCT/US2014/050427 patent/WO2015060924A1/en not_active Ceased
- 2014-08-08 MY MYPI2016701480A patent/MY176246A/en unknown
- 2014-08-08 SG SG10201800001VA patent/SG10201800001VA/en unknown
- 2014-08-08 SG SG11201603042TA patent/SG11201603042TA/en unknown
- 2014-08-08 JP JP2016526009A patent/JP6166471B2/en active Active
-
2016
- 2016-04-21 IL IL245287A patent/IL245287A0/en unknown
-
2017
- 2017-02-07 AU AU2017200832A patent/AU2017200832A1/en not_active Abandoned
- 2017-06-22 JP JP2017121884A patent/JP6453387B2/en active Active
- 2017-08-23 IL IL254123A patent/IL254123A0/en unknown
-
2018
- 2018-12-12 JP JP2018232467A patent/JP6802245B2/en active Active
- 2018-12-26 HK HK18116608.0A patent/HK1257400A1/en unknown
-
2020
- 2020-11-26 JP JP2020196080A patent/JP7136487B2/en active Active
-
2022
- 2022-08-25 JP JP2022134019A patent/JP2022162105A/en active Pending
-
2024
- 2024-02-07 JP JP2024017350A patent/JP2024040304A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY176246A (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| NZ702414A (en) | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions | |
| EA201590371A1 (en) | 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| EA201690287A1 (en) | 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY | |
| EA201890767A1 (en) | C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER APPLICATIONS | |
| MX2020010300A (en) | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| EA201791432A1 (en) | COMPOSITIONS ON THE BASIS OF MONOMETHYLATE PREPARATION | |
| MX2016000294A (en) | Pharmaceutical composition for a sustained release of lanreotide. | |
| EP4302825A3 (en) | Pharmaceutical compositions for treatment of inappetence | |
| EA201591704A1 (en) | NEW SUSTAINABLE SALTS OF PENTADECEPEPTIDE, METHOD OF THEIR PRODUCTION, THEIR APPLICATION IN THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION IN THERAPY | |
| PH12014502065A1 (en) | Vesicular formulations | |
| BR112017002449A2 (en) | treatment of symptoms associated with androgen deprivation therapy | |
| PH12015502727A1 (en) | Methods and compositions for enhancing cognitive performance | |
| MX368641B (en) | Compounds for treating inflammation and pain. | |
| MX358470B (en) | Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections. | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| MX2016002139A (en) | Pharmaceutical composition and use of diethyl (2-cyanoethyl)phosphonate. | |
| PH12015502560B1 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease | |
| MY196155A (en) | Osteoclast Inhibitors for Pain |